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Background: Psoriasis prevalence and characteristics in Asia, Central Europe, and Latin America have not been
thoroughly investigated and there are no large trials for biologic treatments for patients from these regions. The
goal of this analysis was to report clinical response to anti-tumor necrosis factor-alpha treatment in these patients.
Methods: Patients from Argentina, Czech Republic, Hungary, Mexico, Taiwan, and Thailand (N = 171) were included
in this subset analysis of the PRISTINE trial. Patients with stable moderate-to-severe plaque psoriasis were blinded
and randomized to receive etanercept 50 mg once weekly (QW) or biweekly (BIW) for 12 weeks, followed by 12 weeks
of open-label QW treatment with etanercept 50 mg through week 24 (QW/QW vs. BIW/QW). Concomitant methotrexate
(≤20 mg/week) and mild topical corticosteroids or other agents were permitted at the physician’s discretion, in
accordance with therapeutic practice.
Results: As early as week 8, 26.7 % in the etanercept QW group and 44.0 % in the BIW group achieved Psoriasis
Area and Severity Index (PASI) 75. At weeks 12 and 24, respectively, PASI 75 increased to 39.5 % and 62.8 % in the
QW/QW group and 66.7 % and 83.3 % in the BIW/QW group. PASI 75 was significantly different between treatment
groups from week 8 through the end of study (p < 0.05). The Kaplan-Meier estimate of the proportions achieving PASI
75 in QW/QW and BIW/QW groups, respectively, was 27.4 % and 45.8 % through week 8; 41.9 % and 68.7 % through
week 12; and 72.5 % and 95.2 % through week 24.
Conclusions: Treatment with etanercept 50 mg provided rapid relief of psoriasis symptoms in patients from Asia,
Central Europe, and Latin America. A more rapid response was observed in patients who received BIW treatment for
the first 12 weeks which was sustained after reducing to QW dosing for the subsequent 12 weeks. Response rates were
similar to those observed in the overall PRISTINE population.
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Psoriasis is a chronic inflammatory skin condition char-
acterized by exacerbations and remissions and estimated
to affect approximately 125 million people (2–3 %)
worldwide [1]. In the United States, where such data are
available, the prevalence of psoriasis varies among ethni-
city, with 0.47 % of Chinese [2], 1.3 % of African Americans
and 1.6 % of Hispanic affected compared with 3.6 % of
Caucasians [1]. As such, it is possible that patients from
different parts of the world may respond differently to
treatment.
The goal of treatment in psoriasis is to alleviate symp-
toms as rapidly as possible and maintain the response
over time. Current treatment guidelines in both the
United States and Europe support the combination of
topical and systemic therapies, including biologic agents,
in order to achieve these goals [3–6]. Although the ef-
fectiveness of biologic agents is well-established through
clinical trials in the United States and Europe [5–7],
these agents have not been studied extensively in many
parts of the world.
The PRISTINE trial was a multinational, randomized,
double-blind study in patients with moderate-to-severe
plaque psoriasis in which investigators evaluated the effi-
cacy and safety of two dosing regimens of etanercept [8].
This trial included patients from Argentina, Czech
Republic, Hungary, Mexico, Taiwan, and Thailand.
The objective of the subset analysis reported here was
to evaluate the efficacy of etanercept therapy in pa-
tients from countries in Asia, Central Europe, and
Latin America.Fig. 1 PRISTINE study design. BIW: twice weekly; QW: once weeklyMethods
Study details
The details of the PRISTINE trial have been previously
published [8]. Briefly, patients ≥18 years of age with
stable moderate-to-severe plaque psoriasis were ran-
domized to receive 50 mg etanercept subcutaneously ei-
ther once weekly (QW) or twice weekly (BIW) for
12 weeks, after which all patients received open-label,
50 mg etanercept subcutaneously QW for an additional
12 weeks, i.e. QW/QW or QW/BIW dosing groups (Fig. 1).
Concomitant methotrexate was allowed (≤20 mg/week) if
doses were stable from at least 28 days prior to baseline
through the end of study. Only mild topical corticosteroids
were permitted on scalp, axillae and groin for first
12 weeks; topical medications (corticosteroids of all poten-
cies, vitamin D analogues and combination products) were
allowed as needed, at physician’s discretion, during the sec-
ond 12 weeks, consistent with therapeutic practice. Of the
273 patients enrolled in the PRISTINE trial, 171 patients
were eligible for this subset analysis.
The study protocol was reviewed and approved by an
independent Ethics Committee prior to initiation. The
study was conducted in compliance with the ethical
principles of the Declaration of Helsinki and the Inter-
national Conference on Harmonization Good Clinical
Practice Guidelines. The PRISTINE trial is registered on
ClinicalTrials.gov, identifier NCT00663052.
Study endpoints
Primary efficacy was measured as the proportion of pa-
tients achieving 50 %, 75 %, or 90 % improvement in
Table 1 Baseline characteristics of all randomized patients from






Age, years 45.8 (13.0) 44.8 (12.0) 0.581
Male gender, n ( %) 64 (74.4) 63 (74.1) 1.000
Race, n (%) 0.898
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75, and PASI 90, respectively, at weeks 8, 12, and 24.
Other efficacy endpoints included the percentage of pa-
tients who achieved a status of “clear” or “almost clear”
on the Physician’s Global Assessment (PGA) of psoriasis,
time to achieving PGA first “clear” or “almost clear” sta-
tus, and percentage reduction in affected body surface
area (BSA). Health-related quality of life (HRQoL) mea-
sures included Dermatology Life Quality Index (DLQI)
[9], EuroQoL-5 Dimension (EQ-5D™) [10, 11], Work
Productivity and Activity Impairment scale (WPAI) [12]
and Functional Activity in Chronic Therapy (FACIT) [13].
Statistical analyses
For continuous efficacy parameters, treatment groups
were compared in 1-way analysis of variance for baselineFig. 2 Subset analysis design. BIW: twice weekly; BSA: body surface
area; DLQI: Dermatology Life Quality Index; EQ-5D: EuroQoL-5
Dimension; FACIT: Functional Activity in Chronic Therapy; HRQoL:
health-related quality of life; PASI: Psoriasis Area and Severity Index;
PGA: Physician Global Assessment of psoriasis; QW: once weekly;
WPAI: Work Productivity and Activity Impairment scaleparameters or in analysis of covariance models of week
12/24 change from baseline parameters with treatment
group as a factor and baseline measurement as a covari-
ate. For dichotomous or categorical parameters, Fisher’s
exact test was used. The last observation was carried for-
ward for patients for whom data were not available at
any time point.White 44 (51.2) 46 (54.1)
Asian 25 (29.1) 22 (25.9)
Other 17 (19.8) 17 (20.0)
Body weight, kg 87.3 (19.3) 84.5 (17.1) 0.311
Body mass index, kg/m2
Male 28.9 (5.1) 28.2 (4.4) 0.438
Female 32.8 (8.4) 30.4 (6.7) 0.295
Waist to hip ratio
Male 1.0 (0.1) 1.0 (0.1) 0.289
Female 0.9 (0.1) 0.9 (0.1) 0.501
Current smokers, n (%) 29 (33.7) 25 (29.4) 0.622
Psoriasis disease duration, years 17.0 (10.8) 15.8 (7.8) 0.440
PASI total score 22.2 (9.7) 22.4 (9.4) 0.905
PGA score 3.4 (0.8) 3.4 (0.7) 0.955
Affected body surface area, % 38.0 (22.6) 36.9 (19.6) 0.743
History of psoriatic arthritis, n (%) 32 (37.2) 32 (37.7) 1.000
Duration of psoriatic arthritis, years 7.5 (7.1) 7.7 (5.6) 0.903
Secondary diagnosis of diabetes, n (%) 9 (10.5) 12 (14.1) 0.494
Secondary diagnosis of hypertension,
n (%)
37 (43.0) 37 (43.5) 1.000
DLQI score 14.8 (8.4) 14.8 (7.2) 0.967
EQ-5D score 0.6 (0.3) 0.6 (0.3) 0.856
WPAI: % activity impairment due to
problem
39.3 (31.2) 42.6 (30.5) 0.487
WPAI: % impairment while working
due to problem
23.2 (25.0) 25.8 (24.8) 0.603
WPAI: % overall work impairment due
to problem
27.1 (26.0) 27.1 (24.8) 0.999
WPAI: % work time missed due to
problem
8.3 (20.7) 4.8 (19.5) 0.378
FACIT score 35.9 (11.4) 37.3 (9.4) 0.368
aData are given as mean (SD) unless otherwise specified
BIW twice weekly, DLQI Dermatology Life Quality Index, EQ-5D EuroQOL 5
Dimension, FACIT Functional Activity in Chronic Therapy, PASI Psoriasis Area
and Severity Index, PGA Physician Global Assessment of psoriasis, QW once
weekly, WPAI Work Productivity and Activity Impairment scale
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Patients
Of the 273 patients enrolled in the PRISTINE trial, all
171 patients from Asia (Taiwan, n = 25; Thailand, n = 22),
Central Europe (Czech Republic, n = 12; Hungary, n = 50),
and Latin America (Argentina, n = 28; Mexico, n = 34)
were included in the analysis. Since the number of pa-
tients from each region was small, they were pooled to-
gether for this subset analysis (Fig. 2).
The baseline demographics were similar between the
etanercept 50 mg QW/QW and BIW/QW treatment
groups (Table 1). In addition, the history of psoriasis, the
extent of the disease, the presence and duration of psori-
atic arthritis, and baseline HRQoL measures were also
similar between the two groups of patients (Table 1).
The baseline characteristics of the patients in this subset
were comparable to those from the overall PRISTINE
population (Table 2).Table 2 Baseline characteristics of patients from Asia, Central
Europe, and Latin America compared with total PRISTINE
populationa







Age, years 45.3 (12.5) 43.9 (12.7)
Male gender, n (%) 127 (74.3) 190 (69.6)
Ethnicity, n (%)
White 90 (52.6) 174 (63.7)
Asian 47 (27.5) 64 (23.4)
Other 34 (19.9) 35 (12.8)
Body weight, kg 85.9 (18.3) 85.1 (18.6)
Body mass index, kg/m2
Male 28.5 (4.8) 28.3 (4.6)
Female 31.6 (7.6) 29.6 (7.5)
Waist to hip ratio
Male 1.0 (0.1) 1.0 (0.1)
Female 0.9 (0.1) 0.9 (0.1)
Prior smokers, n (%) 57 (33.7) 109 (40.2)
Psoriasis disease duration, years 16.4 (9.4) 17.3 (10.6)
PASI total score 22.3 (9.6) 21.2 (9.4)
PGA score 3.4 (0.8) 3.4 (0.8)
Affected body surface area, % 37.4 (21.1) 33.0 (20.2)
History of psoriatic arthritis, n (%) 64 (37.4) 84 (30.8)
Duration of psoriatic arthritis, years 7.6 (6.3) 8.2 (8.0)
Secondary diagnosis of diabetes, n (%) 21 (12.3) 26 (9.5)
Secondary diagnosis of hypertension,
n (%)
74 (43.3) 97 (35.5)
aData are given as mean (standard deviation) unless otherwise specified
PASI Psoriasis Area and Severity Index, PGA Physician Global Assessment
of psoriasisEfficacy analyses
There were more patients achieving PASI 50, PASI 75,
and PASI 90 in the group that received etanercept
50 mg BIW than in the group that received etanercept
50 mg QW over the time course of the study (Fig. 3).
Statistically significant difference between the two treat-
ment groups was evident as early as week 4 in PASI 50.
Statistically significant difference in PASI 75 was ob-
served by week 8 and in PASI 90 by week 12 (Fig. 3).
After 12 weeks of treatment, i.e. at the end of theFig. 3 Percentage of PASI 50 a, 75 b, and 90 c responders by treatment
group (LOCF data). *p < 0.05; †p < 0.01. BIW: twice weekly; LOCF: last
observation carried forward; PASI: Psoriasis Area and Severity Index;
QW: once weekly
Table 3 Kaplan-Meier rate estimates: proportions of patients achieving first PASI 50, 75, and 90, by treatment group
PASI
Response
% of Patients (95 % CI)
Week 0–8 Week 0–12 Week 0–24
QW/QW n = 86 BIW/QW n = 84 QW/QW n = 86 BIW/QW n = 84 QW/QW n = 86 BIW/QW n = 84
PASI 50 59.5\ (49.3, 70.0) 79.5 (70.3, 87.4) 75.5 (65.8, 84.1) 92.8 (85.9, 97.0) 90.5 (82.8, 95.6) 98.8 (94.2, 99.9)
PASI 75 27.4 (19.1, 38.3) 45.8 (35.8, 57.1) 41.9 (32.2, 53.2) 68.7 (58.6, 78.3) 72.5 (62.5, 81.6) 95.2 (89.1, 98.4)
PASI 90 7.2 (3.3, 15.2) 13.3 (7.6, 22.7) 15.6 (9.4, 25.3) 32.5 (23.6, 43.7) 47.7 (37.5, 59.1) 61.5 (51.2, 71.8)
BIW twice weekly, CI confidence interval, PASI Psoriasis Area and Severity Index, QW once weekly
Fig. 4 Effect on PGA a and BSA b scores in response to etanercept
by treatment group (LOCF data). *p < 0.0001. BIW: twice weekly;
BSA: body surface area; LOCF: last observation carried forward;
PGA: Physician’s Global Assessment; QW: once weekly
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tients in the QW/QW group and 92 %, 67 % and 32 %
in the BIW/QW group achieved PASI 50, PASI 75 and
PASI 90, respectively. Kaplan-Meier estimates of the
proportions of patients achieving first PASI 50, PASI 75
and PASI 90 responses by weeks 8, 12 and 24 also indi-
cate a strong beneficial response in both treatment
groups (Table 3). Improvements from baseline were also
observed in PGA and BSA scores (p < 0.0001) at weeks
12 and 24 in both treatment groups (Fig. 4). By week 12,
36 % and 56 % of patients in the QW/QW and BIW/
QW groups, respectively, exhibited a PGA status of clear
or almost clear (Table 4). By week 24, the number of pa-
tients with clear or almost clear status increased to 57 %
and 71 % in the QW/QW and BIW/QW groups, re-
spectively. For the achievement of first PGA of clear/
almost clear response, there was a statistically significant
difference between the time-to-event curves for the
QW/QW and BIW/QW treatment arms (p = 0.0112)
and a significantly higher median time-to-response for
the QW/QW group (113 days; 95 % confidence interval
[CI]: 85–141) compared with the BIW/QW group
(85 days; 95 % CI: 59–86). The efficacy parameters are
summarized in Table 4.
HRQoL analyses
Statistically significant (p < 0.001) improvements from
baseline in all measures of HRQoL were observed in
both treatment groups by week 12 and were maintained
to week 24 (Table 5). In addition, the difference in the
observed improvement in DLQI and EQ-5D scores at
week 12 between the two treatment groups was statisti-
cally significant (p < 0.05).
Safety analyses
Individual safety analysis by country or region was not
performed since the trial was designed to randomize all
enrolled patients and not stratified by geographic loca-
tion. The complete safety data for the PRISTINE trial
have been reported before [8]. Briefly, etanercept was
well tolerated. The most commonly reported (≥5 % of
patients) treatment-emergent adverse events were naso-
pharyngitis, headache, elevated blood insulin, diarrhea,
injection-site erythema, pharyngitis, arthralgia, fatigueand injection-site reaction. Seven patients of 273 (2.6 %)
reported serious adverse events and nine patients dis-
continued treatment due to an adverse event. There was
no incidence of tuberculosis, opportunistic infections, or
deaths reported.
Discussion
Guidelines for the treatment of psoriasis have been well
established in the United States and Western Europe
[3–6] and, more recently, in the Czech Republic [14]
and Mexico [15]. These same treatment paradigms have
Table 4 Summary of improvements in efficacy measures in response to etanercept by treatment group
Response/Parameter Week 12 Week 24
QW/QW n = 86 BIW/QW n = 84 QW/QW n = 86 BIW/QW n = 84
PASI 50, % of patients (95 % CI) 72.1 (61.4, 81.2) 91.7* (83.6, 96.6) 80.2 (70.2, 88.0) 90.5 (82.1, 95.8)
PASI 75, % of patients (95 % CI) 39.5 (29.2, 50.7) 66.7* (55.5, 76.6) 62.8 (51.7, 73.0) 83.3* (73.6, 90.6)
PASI 90, % of patients (95 % CI) 14.0 (7.4, 23.1) 32.1* (22.4, 43.2) 37.2 (27.0, 48.3) 56.0* (44.7, 66.8)
Adjusted mean change from baseline in total PGA score, mean (SEM) −1.5† (0.1) −2.0*† (0.1) −1.9† (0.1) −2.2*† (0.1)
PGA clear/almost clear, % of patients (95 % CI) 36.0† (26.0, 47.1) 56.0*† (44.7, 66.8) 57.0† (45.8, 67.6) 71.4† (60.5, 80.8)
Adjusted mean % change in affected body surface area, mean (SEM) −14.6† (1.7) −23.2*† (1.7) −21.7† (1.5) 29.6*† (1.5)
Missing data were imputed using the last observation carried forward method
*p < 0.05 between treatment groups at the same time point. †p < 0.01 from baseline within treatment group
BIW twice weekly, PASI Psoriasis Area and Severity Index, PGA Physician’s Global Assessment, QW once weekly, SEM standard error of the mean
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ation that there would be similar responses. However,
there have been few, if any, formal evaluations of re-
sponses to any specific treatment in patients from other
parts of the world. The fact that the prevalence of psor-
iasis in Hispanic, African Americans, and other ethnic
groups is less than half of that observed in Caucasians
(1.4 %–1.6 % vs. 3.6 %, respectively) [1] suggests that it
may be important to at least review and re-evaluate the
responses of patients from other ethnic backgrounds
and countries.
In this post-hoc, subset analysis, we examine the re-
sponses of patients from six countries (Argentina, Czech
Republic, Hungary, Mexico, Taiwan, and Thailand) in
three regions of the world (Asia, Central Europe, and
Latin America) in which there are no current guidelines
for the treatment of psoriasis other than in the Czech
Republic [14] and Mexico [15]. Of the 273 patients ori-
ginally enrolled in the PRISTINE trial, 171 patients were
from these three regions. However, since the number of
patients from each of the six countries was small, they
were pooled for descriptive statistical analyses.
The percentages of patients achieving PASI 50, PASI
75 or PASI 90 in response to etanercept treatment wereTable 5 Summary of improvements in HRQoL measures in response
Adjusted mean change from baseline Week
QW/Q
DLQI, mean (SEM) −8.4†
EQ-5D, mean (SEM) 0.2 (0
WPAI: % activity impairment due to problem, mean (SEM) −19.1
WPAI: % impairment while working due to problem, mean (SEM) −7.5 (
WPAI: % overall work impairment due to problem, mean (SEM) −7.8 (
WPAI: % work time missed due to problem, mean (SEM) −3.4 (
Total FACIT, mean (SEM) 3.2† (0
Missing data were imputed using the last observation carried forward method
*p < 0.05 between treatment groups at the same time point. †p < 0.01 from baseline
BIW twice weekly, DLQI Dermatology Life Quality Index, EQ-5D EuroQoL 5 Dimensio
life, QW once weekly, SEM standard error of the mean, WPAI Work Productivity andnumerically greater in this subset than the correspond-
ing percentages in the overall PRISTINE population [8]
at both the 12- and 24-week time points. Similarly, the
percentage of patients achieving a PGA status of clear or
almost clear in response to etanercept treatment was
also numerically greater in this subset than in the overall
PRISTINE study population. Even though some out-
comes appear to have slightly better responses numeric-
ally for this subpopulation compared with the overall
study population [8], the underlying cause for these dif-
ferences is unclear. This could be related to shorter
psoriatic arthritis disease duration; slightly higher disease
severity, e.g. BSA and PASI, at baseline for this subpopu-
lation, allowing for greater improvement; slightly higher
body mass index and smaller waist-to-hip ratio among
the females in this subpopulation; slightly fewer Cauca-
sians; slightly higher number of patients with secondary
diagnosis of psoriatic arthritis, diabetes or hypertension;
or random chance. Since the study was designed to
randomize all enrolled patients without stratification by
their geographic location, the patients from these six
countries were not homogenously distributed between
the two treatment groups. Thus, any analysis comparing
the responses of the subpopulation from these sixto etanercept by treatment group
12 Week 24
W n = 86 BIW/QW n = 84 QW/QW n = 86 BIW/QW n = 84
(0.5) −10.8† (0.5) −9.5† (0.6) −11.0† (0.6)
.0) 0.3* (0.0) 0.2* (0.0) 0.3* (0.0)
† (2.3) −25.1† (2.3) −22.1† (2.2) −27.3† (2.3)
2.5)† −16.3 (2.6)*† −11.8 (2.0)† −18.8 (2.0)*†
3.3)† −15.1 (3.2)† −13.5 (2.8)† −16.3 (2.8)†
2.6)† 0.4 (2.5)† −6.1 (2.3)† 0.6 (2.3)*†
.7) 4.5† (0.7) 4.5† (0.8) 4.3† (0.8)
within treatment group
n, FACIT Functional Activity in Chronic Therapy, HRQoL health-related quality of
Activity Impairment scale
Kemeny et al. BMC Dermatology  (2015) 15:9 Page 7 of 8countries with those from the rest of the enrolled pa-
tients could introduce bias in the results which could be
random or due to regional differences, e.g., accepted
standard of care.
The Kaplan-Meier estimates for time to first response
also demonstrate the rapidity with which patients in this
subset experienced the benefits of etanercept treatment.
As might be expected, the response time was shorter for
those receiving etanercept BIW (median time 85 days,
95 % CI: 59–86 days) compared with those receiving
etanercept QW during the first 12 weeks of the study
(median time 113 days, 95 % CI: 85–141 days). This
difference was statistically significant based on non-
overlapping 95 % CIs suggesting faster and greater bene-
fit to patients from the BIW dosing regimen than QW
dosing regimen.
Analysis of HRQoL measures demonstrated statisti-
cally significant (p < 0.01) improvement of scores from
baseline in response to etanercept treatment for all pa-
rameters in both treatment groups at both 12 weeks and
24 weeks. Furthermore, the differences in the improve-
ments observed for DLQI and EQ-5D scores at week 12
between the BIW and QW treatment groups were statis-
tically significant (p < 0.05). These data parallel the data
observed for the efficacy analyses for this subset of
patients.
Conclusion
The subset analysis reported here demonstrates that pa-
tients with moderate-to-severe plaque psoriasis from six
countries in Asia, Central Europe and Latin America re-
spond to etanercept treatment in a manner similar to
that observed in patients from the United States and
Western Europe. In all analyses, compared with QW
treatment, BIW treatment appears to be more beneficial
with more rapid and greater response. The results for
this Asian, Central European and Latin American sub-
population of the PRISTINE trial, as well as the overall
study population, showed etanercept was well tolerated
by patients at both the BIW and QW dosages and there
were no differences in safety parameters between the
two treatment groups [8]. In conclusion, this analysis
suggests that the guidelines for the treatment of psoriasis
in the United States and Europe can be applied to popu-
lations from other parts of the world as well.
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